This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.
Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.
Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R et al. Soluble interleukin 2 receptors in patients after bone marrow transplantation. Bone Marrow Transplant 1990; 6: 97–101.
Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185–190.
Grimm J, Zeller W, Zander AR . Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998; 21: 29–32.
Nakamura H, Komatsu K, Ayaki M, Kawamoto S, Murakami M, Uoshima N et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000; 106 (1 Part 2): S45–S50.
Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL . Soluble CD8 during T cell activation. J Immunol 1989; 142: 2230–2236.
Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace DJ, Banks K, Klinenberg JR . Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. J Immunol 1994; 152: 3158–3167.
Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947–955.
Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft versus host disease. Blood 2009; 113: 273–278.
Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B et al. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004; 136: 388–392.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.
Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539–1542.
Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511–5519.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ . Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162–169.
von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803–813.
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364–368.
Sale GE, Shulman HM, McDonald GB, Thomas ED . Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol 1979; 3: 291–299.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Acknowledgements
This work was supported by a Friends Grant from the Children's Healthcare of Atlanta.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
August, K., Chiang, KY., Bostick, R. et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant 46, 601–604 (2011). https://doi.org/10.1038/bmt.2010.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.165
This article is cited by
-
Extracellular vesicles as potential biomarkers of acute graft-vs-host disease
Leukemia (2018)
-
Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines
Annals of Hematology (2017)
-
Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors
International Journal of Hematology (2016)
-
Graft-versus-host disease biomarkers: omics and personalized medicine
International Journal of Hematology (2013)
-
Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease
Annals of Hematology (2013)